In addition, FAM3A supplementation significantly lowered inflammatory markers such as IL1β, IL6, and TNFα both in plasma (Fig. 3e) and AAA tissues (Supplementary Fig. 2e) compared to the matched PBS group. The gene discussed is FAM3A; the disease is triple-A syndrome.